<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1607">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140239</url>
  </required_header>
  <id_info>
    <org_study_id>ABRO_WEI_2021</org_study_id>
    <nct_id>NCT05140239</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study on Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function</brief_title>
  <acronym>AbroSkib</acronym>
  <official_title>Prospective Observational Study on Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Stephan Weidinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, non-randomized, single-arm, 12-weeks observational clinical and translational&#xD;
      trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in transepidermal water loss (TEWL) at one non-lesional and one lesional marker skin area at week 12 (day 84) compared to baseline/week 0 (day 0).</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical score of sodium lauryl sulfate irritant reaction of non-lesional skin at week 12 compared to baseline.</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of epidermal thickness and epidermal differentiation markers (e.g. Keratin 16, Ki67, Filaggrin) of one lesional and one non-lesional marker skin area at week 12 compared to baseline.</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving disease control at week 12 as determined by the ADCT</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of differentially expressed genes/pathways in bulk skin after sodium lauryl sulfate irritant reaction of non-lesional skin at week 2 and week 12 compared to baseline.</measure>
    <time_frame>12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of differentially expressed genes/pathways in keratinocytes from target lesions at week 2 and week 12 as compared to baseline</measure>
    <time_frame>12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stratum corneum biomarker (cytokine) levels at target lesions at week 2 and week 12 compared to baseline and to non-lesional skin.</measure>
    <time_frame>12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Composition of Bacterial Taxa of one lesional and non-lesional marker skin area at week 12 compared to baseline.</measure>
    <time_frame>12 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change of antimicrobial peptide levels at week 12 as compared to baseline</measure>
    <time_frame>12 Weeks</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>AbroSkib Cohort</arm_group_label>
    <description>Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare. The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>Non Interventional</description>
    <arm_group_label>AbroSkib Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin biopsies, skin swabs, tape strips, blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (n=20) with moderate to severe atopic dermatitis who are eligible for and&#xD;
        will receive systemic therapy with abrocitinib by their treating dermatologist as part of&#xD;
        standard healthcare. The choice of therapy is strictly done by the treating dermatologist&#xD;
        only, and the reasons for the choice will be captured by a structured documentation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations&#xD;
&#xD;
          2. Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          3. Diagnosis of chronic atopic dermatitis for at least 1 year prior to enrollment based&#xD;
             on American Academy Criteria&#xD;
&#xD;
          4. Eczema Area and Severity Index (EASI) score ≥12 at baseline visit (Week 0)&#xD;
&#xD;
          5. Investigator Global Assessment (IGA) ≥3 at baseline visit (Week 0)&#xD;
&#xD;
          6. Subject is willing and able to comply with the protocol for the duration of the study&#xD;
&#xD;
          7. Subject receives abrocitinib by the treating dermatologist within routine care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients should not enter the study if any of the following exclusion criteria are&#xD;
        fulfilled:&#xD;
&#xD;
          1. Subject is unable to provide written informed consent or comply with the protocol&#xD;
&#xD;
          2. Concurrent enrolment in another clinical trial where the subject is receiving an IMP&#xD;
             or participation in another clinical trial with investigational product during the&#xD;
             last 30 days before inclusion or 7 half-lives of previously used trial medication,&#xD;
             whichever is longer.&#xD;
&#xD;
          3. Active dermatologic conditions that may confound the diagnosis of AD or would&#xD;
             interfere with assessment of treatment, such as scabies, cutaneous lymphoma, or&#xD;
             psoriasis.&#xD;
&#xD;
          4. Known active allergic or irritant contact dermatitis that is likely to interfere with&#xD;
             the assessment of severity of AD.&#xD;
&#xD;
          5. Having used immunosuppressive/immunomodulating therapy (Systemic&#xD;
             immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine,&#xD;
             azathioprine, mycophenolate mofetil, other Janus kinase inhibitors), systemic&#xD;
             corticosteroid use (excludes topical, inhaled, or intranasal delivery, bleach baths)&#xD;
             during any week within the 4 weeks or tanning beds or phototherapy (narrow band&#xD;
             ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen +&#xD;
             ultraviolet A [PUVA]), within 4 weeks before the baseline visit&#xD;
&#xD;
          6. Treatment of selected skin areas (non-lesional skin at volar forearm and extensor&#xD;
             forearm, lesional skin) with topical corticosteroid or topical calcineurin inhibitor 1&#xD;
             week prior to baseline visit and throughout the study.&#xD;
&#xD;
          7. Treatment of skin areas of examination with emollients 24 hours prior to baseline&#xD;
             visit and throughout the study.&#xD;
&#xD;
          8. Involvement in the planning and/or conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Weidinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKSH Kiel, University of Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan Weidinger, MD</last_name>
    <phone>004943050021163</phone>
    <email>sweidinger@dermatology.uni-kiel.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>UKSH, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.awmf.org/fileadmin/user_upload/Leitlinien/013_D_Dermatologische_Ges/013-027l_S2k_Neurodermitis_Aktualisierung-Systemtherapie_2021-05.pdf</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020 Aug 1;396(10247):345-360. doi: 10.1016/S0140-6736(20)31286-1. Review. Erratum in: Lancet. 2020 Sep 12;396(10253):758.</citation>
    <PMID>32738956</PMID>
  </reference>
  <reference>
    <citation>Moitinho-Silva L, Boraczynski N, Emmert H, Baurecht H, Szymczak S, Schulz H, Haller D, Linseisen J, Gieger C, Peters A, Tittmann L, Lieb W, Bang C, Franke A, Rodriguez E, Weidinger S. Host traits, lifestyle and environment are associated with human skin bacteria. Br J Dermatol. 2021 Sep;185(3):573-584. doi: 10.1111/bjd.20072. Epub 2021 May 18.</citation>
    <PMID>33733457</PMID>
  </reference>
  <reference>
    <citation>Tsoi LC, Rodriguez E, Stölzl D, Wehkamp U, Sun J, Gerdes S, Sarkar MK, Hübenthal M, Zeng C, Uppala R, Xing X, Thielking F, Billi AC, Swindell WR, Shefler A, Chen J, Patrick MT, Harms PW, Kahlenberg JM, Perez White BE, Maverakis E, Gudjonsson JE, Weidinger S. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol. 2020 May;145(5):1406-1415. doi: 10.1016/j.jaci.2019.11.047. Epub 2019 Dec 28.</citation>
    <PMID>31891686</PMID>
  </reference>
  <reference>
    <citation>Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, Szymczak S, Swindell WR, Sarkar MK, Raja K, Shao S, Patrick M, Gao Y, Uppala R, Perez White BE, Getsios S, Harms PW, Maverakis E, Elder JT, Franke A, Gudjonsson JE, Weidinger S. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J Invest Dermatol. 2019 Jul;139(7):1480-1489. doi: 10.1016/j.jid.2018.12.018. Epub 2019 Jan 11.</citation>
    <PMID>30641038</PMID>
  </reference>
  <reference>
    <citation>Möbus L, Rodriguez E, Harder I, Stölzl D, Boraczynski N, Gerdes S, Kleinheinz A, Abraham S, Heratizadeh A, Handrick C, Haufe E, Werfel T, Schmitt J, Weidinger S; TREATgermany study group. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J Allergy Clin Immunol. 2021 Jan;147(1):213-223. doi: 10.1016/j.jaci.2020.06.012. Epub 2020 Jun 29.</citation>
    <PMID>32615169</PMID>
  </reference>
  <reference>
    <citation>Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018 Jun 21;4(1):1. doi: 10.1038/s41572-018-0001-z. Review.</citation>
    <PMID>29930242</PMID>
  </reference>
  <reference>
    <citation>Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8.</citation>
    <PMID>26454361</PMID>
  </reference>
  <reference>
    <citation>Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.</citation>
    <PMID>27690741</PMID>
  </reference>
  <reference>
    <citation>Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.</citation>
    <PMID>28478972</PMID>
  </reference>
  <reference>
    <citation>Abraham S, Haufe E, Harder I, Heratizadeh A, Kleinheinz A, Wollenberg A, Weisshaar E, Augustin M, Wiemers F, Zink A, Biedermann T, von Kiedrowski R, Hilgers M, Worm M, Pawlak M, Sticherling M, Fell I, Handrick C, Schäkel K, Staubach P, Asmussen A, Schwarz B, Bell M, Neubert K, Effendy I, Bieber T, Homey B, Gerlach B, Tchitcherina E, Stahl M, Schwichtenberg U, Rossbacher J, Buck P, Mempel M, Beissert S, Werfel T, Weidinger S, Schmitt J; TREATgermany study group. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany. Br J Dermatol. 2020 Aug;183(2):382-384. doi: 10.1111/bjd.18958. Epub 2020 Apr 13.</citation>
    <PMID>32068242</PMID>
  </reference>
  <reference>
    <citation>Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O'Shea JJ. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i4-i16. doi: 10.1093/rheumatology/key432. Review.</citation>
    <PMID>30806710</PMID>
  </reference>
  <reference>
    <citation>Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7.</citation>
    <PMID>32711801</PMID>
  </reference>
  <reference>
    <citation>Clarysse K, Pfaff CM, Marquardt Y, Huth L, Kortekaas Krohn I, Kluwig D, Lüscher B, Gutermuth J, Baron J. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis. J Eur Acad Dermatol Venereol. 2019 Feb;33(2):367-375. doi: 10.1111/jdv.15301. Epub 2019 Jan 1.</citation>
    <PMID>30357932</PMID>
  </reference>
  <reference>
    <citation>Bieber T. Atopic dermatitis. Ann Dermatol. 2010 May;22(2):125-37. doi: 10.5021/ad.2010.22.2.125. Epub 2010 May 17.</citation>
    <PMID>20548901</PMID>
  </reference>
  <reference>
    <citation>Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109-1122. doi: 10.1016/S0140-6736(15)00149-X. Epub 2015 Sep 13. Review.</citation>
    <PMID>26377142</PMID>
  </reference>
  <reference>
    <citation>Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013 Nov;132(5):1132-8. doi: 10.1016/j.jaci.2013.08.031. Epub 2013 Oct 4.</citation>
    <PMID>24094544</PMID>
  </reference>
  <reference>
    <citation>Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002 Mar;41(3):151-8.</citation>
    <PMID>12010340</PMID>
  </reference>
  <reference>
    <citation>Emmert H, Baurecht H, Thielking F, Stölzl D, Rodriguez E, Harder I, Proksch E, Weidinger S. Stratum corneum lipidomics analysis reveals altered ceramide profile in atopic dermatitis patients across body sites with correlated changes in skin microbiome. Exp Dermatol. 2021 Oct;30(10):1398-1408. doi: 10.1111/exd.14185. Epub 2020 Sep 17.</citation>
    <PMID>32885529</PMID>
  </reference>
  <reference>
    <citation>Baurecht H, Rühlemann MC, Rodríguez E, Thielking F, Harder I, Erkens AS, Stölzl D, Ellinghaus E, Hotze M, Lieb W, Wang S, Heinsen-Groth FA, Franke A, Weidinger S. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol. 2018 May;141(5):1668-1676.e16. doi: 10.1016/j.jaci.2018.01.019. Epub 2018 Feb 5.</citation>
    <PMID>29421277</PMID>
  </reference>
  <reference>
    <citation>Suárez-Fariñas M, Ungar B, Correa da Rosa J, Ewald DA, Rozenblit M, Gonzalez J, Xu H, Zheng X, Peng X, Estrada YD, Dillon SR, Krueger JG, Guttman-Yassky E. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol. 2015 May;135(5):1218-27. doi: 10.1016/j.jaci.2015.03.003. Epub 2015 Mar 31.</citation>
    <PMID>25840722</PMID>
  </reference>
  <reference>
    <citation>Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017 Jul;47(7):1096-1107. doi: 10.1002/eji.201646680. Epub 2017 Jun 21. Review.</citation>
    <PMID>28555727</PMID>
  </reference>
  <reference>
    <citation>Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5.</citation>
    <PMID>30194992</PMID>
  </reference>
  <reference>
    <citation>Retzler J, Smith A, Reaney M, Rout R, Hudson R. Process utilities for topical treatment in atopic dermatitis. Qual Life Res. 2019 Sep;28(9):2373-2381. doi: 10.1007/s11136-019-02174-0. Epub 2019 Apr 3.</citation>
    <PMID>30945132</PMID>
  </reference>
  <reference>
    <citation>Danby SG, Chalmers J, Brown K, Williams HC, Cork MJ. A functional mechanistic study of the effect of emollients on the structure and function of the skin barrier. Br J Dermatol. 2016 Nov;175(5):1011-1019. doi: 10.1111/bjd.14684. Epub 2016 Aug 23.</citation>
    <PMID>27097823</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Stephan Weidinger</investigator_full_name>
    <investigator_title>Vice Head, Department of Dermatology and Allergy</investigator_title>
  </responsible_party>
  <keyword>Skin Barrier</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Dermatology</keyword>
  <keyword>Skin Physiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

